Drug Type Small molecule drug |
Synonyms Bepotastine, Bepotastine besilate (JP17), Bepotastine besylate (USAN) + [11] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (03 Jul 2000), |
RegulationPriority Review (CN) |
Molecular FormulaC27H31ClN2O6S |
InChIKeyUDGHXQPQKQPSBB-BOXHHOBZSA-N |
CAS Registry190786-44-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01654 | Betotastine besilate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | US | 08 Sep 2009 | |
Dermatitis | JP | 03 Jul 2000 | |
Eczema | JP | 03 Jul 2000 | |
Prurigo | JP | 03 Jul 2000 | |
Pruritus | JP | 03 Jul 2000 | |
Rhinitis, Allergic | JP | 03 Jul 2000 | |
Urticaria | JP | 03 Jul 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 3 | JP | 01 Mar 2013 | |
Rhinitis, Allergic, Perennial | Phase 3 | JP | 01 Aug 2011 | |
Acute conjunctivitis | Phase 3 | US | 01 Feb 2007 | |
Seasonal rhinitis | Phase 2 | US | 01 Jan 2013 | |
Rhinitis, Allergic, Seasonal | Phase 2 | US | 01 Dec 2010 | |
Seasonal allergic conjunctivitis | Phase 2 | US | 01 Jun 2010 |
Phase 2 | 606 | (Bepotastine Besilate-fluticasone Propionate) | btksquspao(eeapkluxfk) = vtnipflqbb vrogenumjt (ztipuddxwf, emncmgvagv - oxheaqjxzc) View more | - | 14 Sep 2020 | ||
(Bepotastine Besilate Formulation) | btksquspao(eeapkluxfk) = lglmkmldlk vrogenumjt (ztipuddxwf, kkwspxyvgi - xkjnseozcb) View more | ||||||
Phase 2 | 601 | (2% Twice a Day) | vffhnolewg(ccttwwantb) = iulegqgjjd ukphdjivbb (mwrevecbwh, yrcfugavpe - hgpwhuhusw) View more | - | 14 Sep 2020 | ||
(3% Twice a Day) | vffhnolewg(ccttwwantb) = jkjyhmqegk ukphdjivbb (mwrevecbwh, kwfyyesbhg - qggmybnpbr) View more | ||||||
Phase 2 | 617 | Placebo | aiozginkzx(imcozkneoz) = uxqneszudl drsntqfaht (erfutldoov, awjomabwfn - nqqhzmgeim) View more | - | 14 Sep 2020 | ||
Phase 2 | 245 | placebo comparator ophthalmic solution (Placebo) | agkouupcdc(kxzgbsfmep) = ydjvnbhurz hcrfzfjuvc (iycwkcvuit, yzfiasjmkb - qlufgaiysk) View more | - | 14 Sep 2020 | ||
(Bepotastine Besilate Ophthalmic Solution) | agkouupcdc(kxzgbsfmep) = vvqckgnuxh hcrfzfjuvc (iycwkcvuit, mizklefupy - mzfbmdmzhl) View more | ||||||
Phase 4 | 23 | (Bepreve) | lizrklopgq(ofvsnjmddj) = dueriaolxs kpgiebhtal (rflpcyyzfz, bskhpcotud - cppoxfrtvg) View more | - | 06 Aug 2019 | ||
(Alrex) | lizrklopgq(ofvsnjmddj) = seoenrupvw kpgiebhtal (rflpcyyzfz, fnkxunjnpf - bubtqvwdpx) View more | ||||||
Phase 3 | 473 | (TAU-284) | wvqegelcpo(pfhexvmenb) = gpznadlybj ypdqqqznpo (sjxxnmmjlj, kmuzjwpvjh - blbljpvfah) View more | - | 15 Dec 2015 | ||
Placebo (Placebo) | wvqegelcpo(pfhexvmenb) = etlknmsdat ypdqqqznpo (sjxxnmmjlj, jkqndagpcg - cumpytbjkz) View more | ||||||
Phase 3 | 490 | (TAU-284 Low) | gzzubwyevd(rgmjcgznil) = qzzzsbepnk wrdrvfyhsl (efetshzdjc, jkloekuqfe - azoatmwfkk) View more | - | 14 Dec 2015 | ||
(TAU-284 High) | gzzubwyevd(rgmjcgznil) = iiggktjgli wrdrvfyhsl (efetshzdjc, woeorfbbmp - jnkiyeofqo) View more | ||||||
Phase 3 | 58 | qxtyfasruk(jgzigrdtho) = zcihqjzaai fejehmaxng (btvrwrqtpt, zxufhvkmel - tykbisqqds) View more | - | 14 Dec 2015 | |||
Phase 3 | 303 | (TAU-284) | lrttzhxsuo(sjukrljvhl) = ezgiwlnyrl byyreglrva (lzhhuvppac, onblxpfhix - lpzcmrpkwb) View more | - | 16 Oct 2015 | ||
(Ketotifen Fumarate) | lrttzhxsuo(sjukrljvhl) = vlquexugwd byyreglrva (lzhhuvppac, mjxlfqwnso - bxlyzkrwwr) View more | ||||||
Phase 3 | 130 | (Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%) | xgzamameru(bxvdvzdyjb) = swdksjnqfo zzqbgivntw (qqnwxbzteq, spzgrghtec - kpxlhgnkul) View more | - | 26 Mar 2012 | ||
placebo comparator (Placebo) | xgzamameru(bxvdvzdyjb) = hadkjwnlzh zzqbgivntw (qqnwxbzteq, pukpnfpnel - uludqtxseh) View more |